Showing posts with label Pioneer Institute. Show all posts
Showing posts with label Pioneer Institute. Show all posts

Thursday, October 29, 2026

Who Holds the Cards in America’s Medical Debt Crisis?

By: Marcus J. Hopkins, Health Policy Lead Consultant, ADAP Advocacy

An updated Urban Institute report found that more than 1 in 4 adults (26.6%) reported owing medical debt, including more than 1 in 7 (15.4%) with past-due medical bills or bills they can't pay. Karpman also found that more than half (52.1%) of medical debt was owed to hospitals, though many respondents also held debt for specialist services (41.5%), dental care (37.6%), and general doctor visits (33.5%) (Karpman, 2026).


Medical Debt
Source: Grammarist

These findings echo ADAP Advocacy’s 2025 research, which found that 74% of respondents held medical debt, 39% of whom owed debt to hospitals. ADAP Advocacy’s research went a step further: we asked whether hospitals made patients aware of financial assistance available to help them afford their services. The overwhelming majority of respondents (87.5%) said they either had not been informed or did not remember being informed by a hospital employee that their healthcare services might be eligible for the hospital’s charity care program (Macsata et al., 2025).


One of the only available metrics by which 340B Drug Pricing Program-eligible hospitals can be measured is how much they spend on “charity care”—the provision of healthcare services at cost. Recent research by the policy think tank Pioneer Institute found that 340B hospitals spent just 2.16% of operating expenses on charity care, compared with 2.82% at non-340B hospitals (Popovian et al., 2026).


The American Hospital Association (AHA) responded to these findings with their standard talking points, as 340B hospitals have long argued, that charity care is not the only metric by which they should be measured when serving patients and communities (Hughes, 2026).


Medical Debt
Source: Urban Institute

This statement, however, should be met with significant skepticism.


In addition to arguing that charity care is a poor metric for assessing community benefit, 340B hospitals have also fought vehemently against any efforts to reform the 340B program that require them to be transparent about how the program's revenues are used.


In fact, hospitals appear to believe that any sort of transparency will lead to institutional anaphylaxis. To date, more than half of American hospitals (51%) are out of compliance with a 2019 law requiring all hospitals to establish, update, and make public a list of all standard charges for all items and services (Pifer Parduhn, 2026; Hospital Price Transparency, 2026).


The reality appears to be that hospitals are doing everything in their collective power to avoid making public any information that would hold them accountable. This makes sense when we consider that, although they’re listed as non-profit companies, hospitals are in the business of making profits. Transparency requirements, whether related to pricing or expenditures, would open them to scrutiny and uncomfortable questions about cost and corner-cutting, service reductions, and executive compensation.


And truly, so long as the penalties remain civil monetary penalties (e.g., fines)—particularly if those penalties are as low as $300 per day (with $5,500/day being the maximum) for noncompliance with the price listings (Hospital Price Transparency, 2026)—nothing will change. Until the penalties for noncompliance include severe financial penalties and/or the revocation of eligibility for 340B.


Moreover, medical debt is unlikely to go away and is highly likely to spiral out of control.


Obamacare
Source: The Commonwealth Fund

For patients who purchase health insurance plans through the Affordable Care Act marketplace, insurers are proposing a median 15% premium increase for 2027 after raising premiums by more than 20% in 2026 (Pogue et al., 2026). In addition, the Trump Administration’s affinity for economic tariffs may be contributing to price increases, particularly at hospitals that spend 10.5% of their annual budgets on imported medical supplies and pharmaceutical products (Hider et al., 2026).


Here is where 340B revenues can, and should, go: helping eligible patients defray out-of-pocket medical expenses. In this way, 340B can be the glue holding our healthcare system together. One of the greatest barriers to using the program this way is the opacity of how 340B revenues are used. As the debate over the 340B Program continues, maybe the time has come to shift the program's paradigm to a "money follows the person" framework, modeled after Medicaid's Money Follows the Person (MFP) demonstration. The medical debt crisis...hospital debt crisis... will not go away on its own.


Learn more about ADAP Advocacy’s proposals for common-sense 340B reforms in our recent white paper:


340B PROGRAM: The Glue That Should Hold Our Healthcare System Together


Disclaimer: All funders of the ADAP Advocacy Association are publicly listed on our website. 


Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association; rather, they provide a neutral platform for the author to promote open, honest discussion of public health-related issues and updates.

References:

[1] Hider, A. M., O’Connell, D., & Berlin, N. L. (2025, September 18). Tariffs: Added Strain On The US Health Care System. Health Affairs: Forefront. https://www.healthaffairs.org/content/forefront/tariffs-added-strain-us-health-care-system

[2] Hospital Price Transparency, 45 C.F.R. pt. 180 (2026). https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-E/part-180

[3] Hughes, J. (2026, September 25). 340B hospitals lag behind peers in charity care spending: report. Newton, MA: Healthcare Dive: News: Dive Brief. https://www.healthcaredive.com/news/340b-hospitals-lag-behind-peers-in-charity-care-spending-report/831394/

[4] Karpman, M. (2026, October 06). More than One-Quarter of US Adults Had Medical Debt in 2025. Washington, DC: The Urban Institute: Research. https://www.urban.org/research/publication/more-one-quarter-us-adults-had-medical-debt-2025

[5] Macsata, B. M., Laws, J., Hopkins, M. J. & Sosa, J. (2025, April). Patient Medical Debt: Findings from Quantitative Patient Survey in the United States. Washington, DC: ADAP Advocacy. https://www.adapadvocacy.org/s/2025_ADAP_Project_RW_340B_Asset_17_Medical_Debt_Survey_Report_04-23-25-gfhj.pdf

[6] Macsata, B. M., Anthony, G., Hopkins, M. J., & Sosa, J. (2026, June). 340B Program: The Glue That Should Hold Our Healthcare System Together. Washington, DC: ADAP Advocacy. https://www.adapadvocacy.org/s/2026_ADAP_Project_RW_340B_Asset_32_340B_Glue_Should_Hold_Healthcare_Together_061526.pdf

[7] Pifer Parduhn, R. (2026, September 11). More than half of hospitals still not fully compliant with price transparency rules: report. Newton, MA: Healthcare Dive: News: Dive Brief. https://www.healthcaredive.com/news/hospital-compliance-price-transparency-regulations-pra-report/830087/

[8] Pogue, S., Knapp, A., & Giovanelli, J. (2026, October 08). More ACA Premium Spikes to Come in 2027 Amid Federal Policy Changes. New York, NY: The Commonwealth Fund: Blog. https://www.commonwealthfund.org/blog/2026/more-aca-premium-spikes-come-2027-amid-federal-policy-changes

[9] Popovian, R., Sydor, A. M., Czubaruk, K., Walker, M., & Smith, W. (2026, September 24). The 340B Accountability Gap: Charity Care, Uncompensated Care, and Medicaid Patient Volume Among 340B and Non-340B Hospitals: What the Data Mean for 340B Accountability and Reform. Boston, MA: The Pioneer Institute: Pioneer Health. https://pioneerinstitute.org/wp-content/uploads/2026/09/2026-09-08-Cancer-Care-340B-Paper.pdf

Thursday, October 8, 2026

340B: The Glue That Should Hold Our Healthcare System Together

By: Marcus J. Hopkins, Health Policy Lead Consultant, ADAP Advocacy

In June 2026, ADAP Advocacy released its latest policy paper—340B Program: The Glue That Should Hold Our Healthcare System Together—focusing on the explosive growth of the 340B Program from just 1,000 covered entities (CEs) and 503 contract pharmacies (CPs) in 1992 to over 53,000 CEs and 34,840 CPs in 2024. In addition to examining this growth and its causes, ADAP Advocacy also provided concrete recommendations to ensure the 340B Program can function in perpetuity (Macsata, et al., 2026). The policy paper is the latest in a series supporting the organization's argument that the 340B Program is too big to fail.


Glue bottle with "340B" label
Source: ADAP Advocacy

ADAP Advocacy argues that, because the 340B Program spans more than 42,000 healthcare organizations and 32,000 pharmacies, it should be the glue that holds our healthcare system together. Instead, the 340B program has essentially become a slush fund for unscrupulous CEs—primarily hospitals—that lines executives’ pockets while cutting corners, costs, and services for both staff and patients. That’s not to suggest the program isn’t vitally important, or that there aren’t plenty of good actors…CEs…in the 340B space, because it is, and there are. The fact of the matter is a healthcare program of this size and magnitude cannot be entrusted to good faith alone; rather, improved transparency guardrails are needed to ensure its success and ultimately its intended beneficiaries: patients.


Primary Drivers of Growth:


ADAP Advocacy identified several key drivers of growth in the 340B program, including:

  • The expansion of eligibility categories;
  • The expansion of large health systems;
  • The growing utilization by CEs of off-site clinics and child sites; and
  • The explosive growth of Pharmacy Benefit Managers (PBMs) and contract pharmacies operating in the American healthcare space as third-party administrators for CEs

Policy Proposals


ADAP Advocacy also recommended several policy proposals to address the myriad issues facing the program, including:

  • The implementation of a program-wide rebate model, in which drugs are purchased at full price up front, and rebates are provided by manufacturers at a later date;
  • The consideration of a rebate “sales draw” under the program-wide rebate model that accounts for agencies with smaller annual operating revenues (e.g., those with less than $2 million);
  • Mandatory reporting requirements for CEs, including how revenues have been used to improve patient care, reduce drug costs, or expand community services;
  • Clearly defining “patient” in the statute—who qualifies as a patient, and which purchases qualify for 340B rebates; and
  • Establishing an enforcement mechanism with real teeth and penalties ranging from civil monetary penalties to loss of 340B eligibility.

Each proposal is designed to ensure 340B revenues are used for patients in need, as intended by those who created the program. And these changes are long overdue.


Scale with money on one side and Rx drugs on the other side
Source: ADAP Advocacy | iStock

In 2025, 340B drugs exceeded $179.5 billion in list prices, with hospitals as the biggest cost driver (Martin et al, 2026). The 340B Program is immensely significant, and rising waste, fraud, and abuse pose an increasing risk. Because the American healthcare system is highly interdependent, a weakness in one sector can have widespread repercussions, making the 340B Program's impact especially important. 


Research published in September 2026 by the Pioneer Institute found that hospitals participating in the 340B Program spent an average of just 2.16% of their operating expenses on charity care, compared to 2.82% at non-340B hospitals. It also found that 340B hospitals spent just 1.6% of operating expenses on care for uninsured patients, compared with 2.26% at non-340B hospitals (Popovian et al., 2026).


Popovian et al. are quick to point out that their findings do not suggest that participating in the 340B Program “causes” hospitals to provide less charity care or care at cost; rather, their findings demonstrate that the 340B Program’s drug discounts, savings, and revenues do not reliably translate into providing more help for patients (either in terms of healthcare provision or lower costs), and that current reporting requirements are insufficient to ensure that 340B revenues are being appropriately utilized in ways that comport with either the letter or intent of the statute.


Pioneer Institute report cover
Source: Pioneer Health

Last month, ADAP Advocacy launched a national advocacy campaign focused on the data and findings of its most recent 340B white paper, including infographics, social media posts, op-eds, and video content. The campaign is patient-centric in that it informs patients, regardless of their chronic health condition or rare disease, why they can no longer sit on the sidelines and watch the pharmaceutical industry and big hospital systems duke it out over what is in our best interest. Nothing about us, without us!


Disclaimer: All funders of the ADAP Advocacy Association are publicly listed on our website. 


Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association; rather, they provide a neutral platform for the author to promote open, honest discussion of public health-related issues and updates.

References:

[1] Macsata, B. M., Anthony, G., Hopkins, M. J., Sosa, J. (2026, June). 340B Program: The Glue That Should Hold Our Healthcare System Together. Nags Head, NC: ADAP Advocacy: Policy Center: 340B: Policy Papers. https://www.adapadvocacy.org/s/2026_ADAP_Project_RW_340B_Asset_32_340B_Glue_Should_Hold_Healthcare_Together_061526.pdf

[2] Martin, R., Karne, H., Zen, S. (2026, June), The Size and Growth of the 340B Program in 2025. IQVIA. https://www.iqvia.com/-/media/iqvia/pdfs/us/white-paper/2026/iqvia-size--growth-of-340b-in-2025-white-paper-2026.pdf

[3] Popovian, R., Sydor, A. M., Czubaruk, K., Walker, M., & Smith, W. (2026, September 24). The 340B Accountability Gap: Charity Care, Uncompensated Care, and Medicaid Patient Volume Among 340B and Non-340B Hospitals: What the Data Mean for 340B Accountability and Reform. Boston, MA: The Pioneer Institute: Pioneer Health. https://pioneerinstitute.org/wp-content/uploads/2026/09/2026-09-08-Cancer-Care-340B-Paper.pdf